ReviewSignal transduction and targeted therapy2025
Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.
Review in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Tumour-Associated Neutrophils in Colorectal Cancer: a Systematic Review, Meta-analysis, and Comprehensive Literature Review.Journal of gastrointestinal cancer · 2026Pooled it
- Immune-inflammatory indices as predictors of pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of observational studies.World journal of surgical oncology · 2026Pooled it
- An immuno-chemotherapeutic bone scaffold for tumor eradication and bone regeneration in drug-resistant osteosarcoma.Bioactive materials · 2026Article
- CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Post-Treatment NLR and SII Associations with Response and Progression-Free Survival After Neoadjuvant Disitamab Vedotin Plus PD-1 Blockade in Muscle-Invasive Bladder Cancer: A Real-World Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Human Group IIA Secreted Phospholipase AInternational journal of molecular sciences · 2026Review
- Reprogramming the Immunosuppressive Microenvironment in Triple-Negative Breast Cancer via FAP-Targeted Nanoprobes for Multimodal Imaging and Photothermal Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Metabolic-epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment.Experimental & molecular medicine · 2026Review
- Construction of a risk model based on folate metabolism-related genes to predict prognosis and immunological characteristics of stomach adenocarcinoma.Discover oncology · 2026Article
- LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cellular architecture and neighborhood-informed virtual spatial tumor profiling from histopathology.Cell · 2026Article
- From Bone Marrow Reserve to Metastatic Niche: How Neutrophil-Lineage Cells Shape Skeletal Colonization.International journal of molecular sciences · 2026Review
- CD300ld on pathologically activated neutrophils promotes tumor immune suppression by binding phosphatidylserine on CD8Nature cancer · 2026Article
- Metabolic enzymes and immune receptors as emerging checkpoints in breast cancer: mechanisms, clinical trials, and therapeutic implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Predictive value of the preoperative systemic immune-inflammation index for primary chemotherapy resistance risk in patients with advanced gastric cancer.Translational cancer research · 2026Article
- A Multicellular Coordinated Network Driving Lymphovascular Space Invasion in Endometrioid Endometrial Carcinoma.Cell proliferation · 2026Article
- New Insights Into the Role of Neutrophils in Lymphoma.Cancer medicine · 2026Review
- Migrasomes program tissue microenvironment: from physiology to oncology, future perspectives in clinical advances.Journal of the National Cancer Center · 2026Review
- Development and validation of a biopsy-based model using tumor-associated neutrophils to predict neoadjuvant chemotherapy response in osteosarcoma: a large single-center retrospective cohort study.Journal of bone oncology · 2026Article
- The microbiome across the prostate disease continuum: from health and BPH to prostatitis/CPPS and cancer.Oncogene · 2026Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Neutrophils are the first line of defense in nonspecific immunity (innate immunity) and interact with other immune cells to participate in specific defense mechanisms (adaptive immunity). Studies have shown that the tumor microenvironment (TME) mediates tumor development and recruits neutrophils into tumors to become tumor-associated neutrophils (TANs), an important part of TME, and achieve extended lifespan. TANs can be differentiated into the antitumor or protumor phenotype, and play an important role in tumor occurrence, proliferation and recurrence, invasion and metastasis, angiogenesis, cell necrosis, and so on. Here, we summarize the TAN origin and subtypes found through Single-cell RNA sequencing analysis in different types of tumors in recent literature, and the molecular mechanisms underlying their antitumor and protumor effects on tumors. We focus on the interaction between TANs and immunosuppressive or immunostimulatory TME, as well as signal pathways such as transforming growth factor β (TGF-β) associated with TAN phenotype transition. Based on the summarized mechanisms, we focus on the potential application and latest strategies of TAN-based immunotherapy, chemotherapy, and combination therapy in the preclinical study and clinical trials of tumors. The discussion on promising therapy encompasses five key areas: inhibition of the tumor-promoting effect of TANs, enhancement of the antitumor effect of TANs, targeting the interaction between TANs and the TME, reprogramming of TANs, and drug delivery carriers. Finally, we discuss the potential of TANs and their related markers as emerging biomarkers for predicting the prognosis of cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.